<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908713</url>
  </required_header>
  <id_info>
    <org_study_id>FIS 2003-CA</org_study_id>
    <nct_id>NCT00908713</nct_id>
  </id_info>
  <brief_title>Corticoids in Severe Community-Acquired Pneumonia (CAP)</brief_title>
  <official_title>Corticoids in Severe Community-acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy
      in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the
      study is that glucocorticoids can modulate the excessive inflammatory response in patients
      with severe CAP without any significant side effects, showing a benefit in the percentage of
      non-response to the empiric antimicrobial treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Community acquired pneumonia (CAP) is associated with a local and systemic inflammatory
      response conducted by different pro and counter inflammatory cytokines. The evolution of the
      infection is mainly dependent on the intensity of the inflammatory response. The AIM of the
      project is to determine the clinical usefulness of methylprednisolone treatment (0,5 mg/ Kg
      weight every 12h for 5 days in patients with severe CAP and an excessive inflammatory
      response( patients identified based on a cut-off point of the reactive C protein (RCP) of 15
      mg/dl). A randomized double blind placebo controlled study with two arms will be performed:
      The study group (patients with excessive inflammatory response) will receive
      methylprednisolone + antibiotics. Control group will receive placebo + antibiotics. Patients
      older than 18 years with Fine V pneumonia will be recruited. Clinical data and prognostic
      factors (APACHE II and, SOFA scores, etiology, mortality at ICU and at 28 days) will be
      collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of non-response to empiric antimicrobial treatment</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Community-Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days</description>
    <arm_group_label>methylprednisolone</arm_group_label>
    <other_name>solumoderin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride 0.9% 10 mL every 12 h for 5 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe community-acquired pneumonia Fine V

          -  CRP &gt;=15 mg/100 mL

        Exclusion Criteria:

          -  Major contraindications for corticosteroids, such as uncontrolled diabetes,
             immunosuppression

          -  Previous glucocorticoid treatment during the previous month

          -  Documented extrapulmonary infection

          -  Previous hospitalization in the previous month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Agusti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic, Barcelona,Spain.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Servei Pneumologia. Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servei Pneumoloiga. Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.idibapsrespiratoryresearch.org/</url>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Carlos Agusti</investigator_full_name>
    <investigator_title>Consultor Senior</investigator_title>
  </responsible_party>
  <keyword>Severe CAP</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>CAP Fine V with C-reactive protein &gt;= 15 mg/100 mL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

